Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis

Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis

Abstract Impending myasthenic crisis (IMC) is an emergent situation requiring aggressive management to prevent patients from developing myasthenic crisis (MC) in patients with myasthenia gravis (MG). Efgartigimod has been proved to be well tolerated and efficacious in MG patients. The present study...

Full description

Bibliographic Details
Main Authors: Jing Ma, Huiqiu Zhang, Junsen Zhao, Menghan Su, Yingna Feng, Xiaoli Yuan, Dan Liu, Xiaomin Pang, Rongjuan Zhao, Juan Wang, Weisong Duan, Xueli Chang, Junhong Guo, Wei Zhang
Format: Article
Language:English
Published: Nature Portfolio 2024-11-01
Series:Scientific Reports
Subjects:
Myasthenia gravis
Impending myasthenic crisis
Efgartigimod
IVIg
Efficacy
Online Access:https://doi.org/10.1038/s41598-024-79918-7

Internet

https://doi.org/10.1038/s41598-024-79918-7

Similar Items